The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature

Anja Hviid Simonsen; Bea Kuiperij; Omar Mukhtar Ali El-Agnaf; Sebastian Engelborghs; Sanna Kaisa Herukka; Lucilla Parnetti; Irena Rektorova; Eugeen Vanmechelen; Elisabeth Kapaki; Marcel Verbeek; Brit Mollenhauer

doi:10.2217/BMM.14.105

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature

Anja Hviid Simonsen, Bea Kuiperij, Omar Mukhtar Ali El-Agnaf, Sebastian Engelborghs, Sanna Kaisa Herukka, Lucilla Parnetti, Irena Rektorova, Eugeen Vanmechelen, Elisabeth Kapaki, Marcel Verbeek, Brit Mollenhauer

Research output: Contribution to journal › Article › peer-review

77 Citations (Scopus)

Abstract

The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

Original language	English
Pages (from-to)	19-34
Number of pages	16
Journal	Biomarkers in Medicine
Volume	10
Issue number	1
DOIs	https://doi.org/10.2217/BMM.14.105
Publication status	Published - Jan 2016
Externally published	Yes

Keywords

CSF
ELISA
Parkinson's disease
biomarker
diagnosis
α-synuclein

ASJC Scopus subject areas

Drug Discovery
Clinical Biochemistry
Biochemistry, medical

Access to Document

10.2217/BMM.14.105

Cite this

Simonsen, A. H., Kuiperij, B., El-Agnaf, O. M. A., Engelborghs, S., Herukka, S. K., Parnetti, L., Rektorova, I., Vanmechelen, E., Kapaki, E., Verbeek, M., & Mollenhauer, B. (2016). The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature. Biomarkers in Medicine, 10(1), 19-34. https://doi.org/10.2217/BMM.14.105

@article{b4fe59a5f7c34d9bb3844483e43bcab9,

title = "The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature",

abstract = "The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.",

keywords = "CSF, ELISA, Parkinson's disease, biomarker, diagnosis, α-synuclein",

author = "Simonsen, {Anja Hviid} and Bea Kuiperij and El-Agnaf, {Omar Mukhtar Ali} and Sebastian Engelborghs and Herukka, {Sanna Kaisa} and Lucilla Parnetti and Irena Rektorova and Eugeen Vanmechelen and Elisabeth Kapaki and Marcel Verbeek and Brit Mollenhauer",

note = "Publisher Copyright: {\textcopyright} 2015 Future Medicine Ltd.",

year = "2016",

month = jan,

doi = "10.2217/BMM.14.105",

language = "English",

volume = "10",

pages = "19--34",

journal = "Biomarkers in Medicine",

issn = "1752-0363",

publisher = "Future Medicine Ltd.",

number = "1",

}

TY - JOUR

T1 - The utility of α-synuclein as biofluid marker in neurodegenerative diseases

T2 - A systematic review of the literature

AU - Simonsen, Anja Hviid

AU - Kuiperij, Bea

AU - El-Agnaf, Omar Mukhtar Ali

AU - Engelborghs, Sebastian

AU - Herukka, Sanna Kaisa

AU - Parnetti, Lucilla

AU - Rektorova, Irena

AU - Vanmechelen, Eugeen

AU - Kapaki, Elisabeth

AU - Verbeek, Marcel

AU - Mollenhauer, Brit

PY - 2016/1

Y1 - 2016/1

N2 - The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

AB - The discovery of α-synuclein (α-syn) as a major component of Lewy bodies, neuropathological hallmark of Parkinson's disease (PD), dementia with Lewy bodies and of glial inclusions in multiple system atrophy initiated the investigation of α-syn as a biomarker in cerebrospinal fluid (CSF). Due to the involvement of the periphery in PD the quantification of α-syn in peripheral fluids such as serum, plasma and saliva has been investigated as well. We review how the development of multiple assays for the quantification of α-syn has yielded novel insights into the variety of α-syn species present in the different fluids; the optimal preanalytical conditions required for robust quantification and the potential clinical value of α-syn as biomarker. We also suggest future approaches to use of CSF α-syn in neurodegenerative diseases.

KW - CSF

KW - ELISA

KW - Parkinson's disease

KW - biomarker

KW - diagnosis

KW - α-synuclein

UR - http://www.scopus.com/inward/record.url?scp=84951806008&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84951806008&partnerID=8YFLogxK

U2 - 10.2217/BMM.14.105

DO - 10.2217/BMM.14.105

M3 - Article

C2 - 26314196

AN - SCOPUS:84951806008

SN - 1752-0363

VL - 10

SP - 19

EP - 34

JO - Biomarkers in Medicine

JF - Biomarkers in Medicine

IS - 1

ER -

The utility of α-synuclein as biofluid marker in neurodegenerative diseases: A systematic review of the literature

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this